A Meta-Analysis on Presynaptic Changes in Alzheimer's Disease
Anne Anschuetz1, Karima Schwab1, Charles R Harrington1,2
1School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.
Journal of Alzheimer'S Disease : JAD
|December 11, 2023
Summary
Alzheimer's disease (AD) causes significant loss of presynaptic proteins, particularly in the temporal and frontal cortex. This meta-analysis confirms this loss and identifies specific protein families, like synaptosome-associated proteins, as most affected.
Area of Science:
- Neuroscience
- Molecular Biology
- Pathology
Background:
- Synaptic dysfunction, characterized by the loss of synaptic proteins, is a hallmark of Alzheimer's disease (AD).
- Previous research indicates a greater impact on presynaptic machinery compared to postsynaptic proteins.
- However, the extent of presynaptic protein loss in AD exhibits significant variability across different brain regions and specific proteins.
Conclusions:
- The findings corroborate existing literature on presynaptic protein loss in Alzheimer's disease.
- This study provides a more detailed characterization of the most impacted proteins and presynaptic functions in AD pathology.
Related Concept Videos
01:26Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195